Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly (LLY.N), opens new tab. Novo shares have fallen sharply over the past year.
"The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement.
"This is related to lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO (International Operations) markets," it said.
Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13%-21% forecast range. It also lowered its operating profit growth estimate to 10%-16%, from 16-24% previously.
Sales rose 18% year-on-year in both the second quarter and the first half of the year, Novo said.
Its operating profit increased by 40% in the April-June quarter and by 29% in the first half, the company added.
Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company in 2024, peaking at about 615 billion euros, but the value has since fallen by more than half.
CEO Lars Fruergaard Jorgensen was ousted in May by Novo and its controlling shareholder, the Novo Nordisk Foundation, but will remain in his position until a successor is appointed.
The company is scheduled to release full second-quarter earnings on August 6.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 minutes ago
- Daily Mail
Revealed: Viktor Gyokeres' surprise move, ten days before Swedish star completed £70m Arsenal transfer
Viktor Gyokeres reportedly set up a company in London almost two weeks before his move to Arsenal was finalised. The Gunners' interest in the prolific Swede had been obvious from the start of the summer window, but negotiations over a deal went on for weeks. Amid interest from rivals Manchester United, the delays must have left Arsenal supporters wondering whether they'd ever finalise a deal, let alone complete a transfer in time for next season. But it seems for the man himself the move was never in-doubt, as Gyokeres registered a new London-based promotions company 10 days before he signed on the dotted line on July 26, according to The Times. The company was registered on July 16 and is expected to handle the striker's image rights income. Its title, VG9 Productions Ltd, takes inspiration from Gyokeres' initials and the number he wore during his two seasons at Sporting Lisbon. It was thought that the Swede would have preferred the No 9 at Arsenal - currently occupied by Gabriel Jesus - but later expressed his desire to follow in the footsteps of Thierry Henry with No 14. After completing his £64m move last weekend, Gyokeres jetted off to Asia to meet his new team-mates on their pre-season tour of Asia. His debut came on Thursday against rivals Tottenham Hotspur, with the frontman afforded 20 or so minutes off the bench as he builds his fitness ahead of the new season. Arsenal begin their campaign with a difficult away fixture at Old Trafford on August 16. He signs with a heap of expectation on his shoulders after slotting home an incredible 97 goals in 102 appearances in Lisbon. The Gunners' longing for a proven frontman has been well- documented amid the struggles of Gabriel Jesus since his move from Manchester City. Mikel Arteta expressed his delight that he and club officials finally got their man last week, saying: ''We're absolutely delighted to welcome Viktor Gyokeres to the club. The consistency he has shown in his performances and availability have been outstanding, and his goal contributions speak for themselves. 'Viktor has so many qualities. He is a quick and powerful presence up front, with incredible goalscoring numbers at club and international levels. 'He brings a clinical edge with a high conversion rate of chances into goals, with his intelligent movement in the box making him a constant threat. 'We're excited about what Viktor brings to our squad and are looking forward to start working with him. We welcome Viktor and his family to Arsenal.' Sporting Director Andrea Berta added: 'We are so pleased with the excellent deal we have completed to bring Viktor Gyokeres to the club. 'Viktor is an exceptional talent and has consistently demonstrated he has the qualities and winning mentality required of a top-level centre-forward. 'His physicality, intelligence and work ethic make him a perfect fit for our vision. We are confident Viktor will have a major impact on the pitch and become an important figure in our dressing room. Welcome, Viktor!'
Telegraph
32 minutes ago
- Telegraph
Streeting should ‘channel Thatcher' and introduce prostate screening
Wes Streeting should 'channel Margaret Thatcher ' and introduce screening for prostate cancer without delay, one of the world's leading experts has said. Prof Jonathan Waxman, the founder of the charity Prostate Cancer UK, says the Health Secretary should learn from Thatcher's decision to introduce routine mammograms for women, which he said had saved 3,000 lives a year since they were introduced in 1988. The Telegraph has launched a campaign calling for the introduction of targeted screening for prostate cancer so those at high risk are automatically offered tests. Prostate Cancer UK has submitted evidence in favour of the policy to the UK National Screening Committee (UKNSC), which is currently considering the matter, with a decision expected later this year. Writing for The Telegraph, Prof Waxman said: 'There are interesting parallels between the prostate cancer and breast cancer screening stories. 'In the 1970s, before breast cancer screening was introduced by Government dictat, the medical consensus was, and, you have guessed it, that early diagnosis through screening mammography would not save lives. 'Mrs T, regardless of the medical consensus, waved her handbag at the doctors, ignored the consensus, and launched a screening programme for breast cancer. And the result? Screening mammography, together with treatment advances, has led to a massive improvement in survival from breast cancer. 'Before screening, just 65 per cent of patients with breast cancer survived and now over 80 per cent are cured as a result of early detection and better treatment. 'And how does this improvement manifest in the real world? Around 3,000 fewer women die each year in the UK from breast cancer than before the screening programme was introduced.' The emeritus professor at Imperial College London said Prostate Cancer UK led a consortium of men's health charities to collectively inform the committee on the importance of targeted screening for those at highest risk. But he said the NHS should act now so that GPs do far more to help men at risk of prostate cancer. He urged the NHS to rewrite its guidance so that family doctors are told to proactively start conversations with men about the PSA blood tests which can detect the disease. Current guidance says that men can ask for a test, though some GPs rebuff them. For younger men, including those with a family history of disease, offering a test is down to the clinical judgment of GPs about. In both cases, the onus is on patients to seek help in the first place, with many men including those with family histories of prostate cancer unaware they are at heightened risk of the disease. Prof Waxman said the NHS should rewrite its advice so that GPs are told that they should bring up prostate cancer with all patients who might be at extra risk. He added that the guidelines should suggest that GPs start conversations with men from the age of 45 at highest risk, so those who wish to can obtain a PSA test. 'This puts the power of informed choice back in the hands of men who need it the most and is a crucial step on the path to early diagnosis,' he says. In the past, screening advisers have rejected the practice on the grounds that the tests are too unreliable, and could result in too many men undergoing needless procedures. However, in recent years the back-up diagnostics used to confirm the initial test findings have significantly improved. A Department of Health and Social Care spokesman said: 'This Government has been clear we would like to see screening in place, but the decision must be evidence-led. 'The UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer. 'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research – GPs should consider risk factors and use clinical judgment when considering if patients need a prostate cancer test.' Prostate cancer is a lot more than a nuisance By Jonathan Waxman Sixty years ago, around 10,000 people in the UK were diagnosed annually with prostate cancer. Currently over 50,000 men are diagnosed each year and prostate cancer has the dreadful distinction of being the commonest cancer in men. In parallel, the number of prostate cancer deaths has increased from 3,300 to over 12,000 men annually. So, what to do? We can hope that the treatment of prostate cancer will improve and improve, and cures are found. Treatment is getting better. Thankfully, in 2025, well over 80 per cent of men with prostate cancer that has not spread beyond the prostate will be cured and the duration of survival for men with cancer that has spread has doubled compared with 25 years ago. These improvements have come because of modern medicine's marvellous miracles, developing from brilliant university research and big pharma's R & D. Prostate Cancer UK has invested over £120m in research over the years. But clearly despite the gloss of shiny medical breakthroughs, prostate cancer remains a fundamentally unpleasant problem, and a lot more than a nuisance. What can be done? Find it early, you say? Yes, that would seem logical. How do we do this? Well, if we want to find prostate cancer early then the obvious answer is to screen for prostate cancer. There is no UK screening programme for the early detection of prostate cancer, a cancer which is often without symptoms. The National Screening Committee is currently considering the role of screening for prostate cancer. Prostate Cancer UK has led a consortium of men's health charities to collectively inform the committee, which advises government, on the importance of targeted screening for those at highest risk. There are interesting parallels between the prostate cancer and breast cancer screening stories. In the 1970s, before breast cancer screening was introduced by Government dictat, the medical consensus was, and, you have guessed it, that early diagnosis through screening mammography would not save lives. Mrs T, regardless of the medical consensus, waved her handbag at the doctors, ignored the consensus, and launched a screening programme for breast cancer. And the result? Screening mammography together with treatment advances have led to a massive improvement in survival from breast cancer. Before screening, just 65 per cent of patients with breast cancer survived and now over 80 per cent are cured as a result of early detection and better treatment. And how does this improvement manifest in the real world? Around 3000 fewer women die in the UK from breast cancer each year than before the screening programme was introduced. To return to the debate on screening for prostate cancer. We are now at a critical inflection point in the history of prostate cancer screening. Last year, Prostate Cancer UK published research that showed prostate cancer diagnosis is safer and more accurate than ever before, and this in part is thanks to research the charity funded leading to MRI – Magnetic Resonance Imaging – being introduced into the diagnostic pathway. The National Screening Committee, under the iron baton of its excellent chair, is currently deliberating on the evidence for and against screening for prostate cancer and will issue a report this year. In heavily trailed remarks, Wes Streeting has indicated that he is in favour of screening but not for everyone, just for selective high risk groups of men. We at Prostate Cancer UK welcome this ministerial support, for it is also our view that there is a need for screening, and we believe the evidence is now there for targeted screening. We welcome his remarks at a time when we are about to launch TRANSFORM, a multi-centre screening trial using sophisticated technologies based on current diagnostic tools, an adaptive trial that is open to new screening tests. Prostate Cancer UK's trial invests £42m in a very long-term campaign to assess the survival benefits of modern screening methods. So, who are Mr Streeting's selective high risk groups of men at increased risk of prostate cancer? These are men with family histories of prostate cancer who constitute 1 to 5 per cent of all diagnosed patients, and black men, who have a one in four risk of prostate cancer, which is twice the risk of white men. What to do whilst we await the Screening Committee's conclusions? Currently GP guidelines concerning testing for prostate cancer are outdated. We urgently need these NHS guidelines updated to empower GPs to proactively start conversations about PSA testing with men from the age of 45 at highest risk. This puts the power of informed choice back in the hands of men who need it the most and is a crucial step on the path to early diagnosis. So, yes, prostate cancer is a bit of a nuisance, but let us see if we can do something about that nuisance. Prof Jonathan Waxman OBE is the founder and president of Prostate Cancer UK
Telegraph
32 minutes ago
- Telegraph
An insider's guide to DAF, by owners of the quirky Dutch cars
While DAF Trucks have been a market leader for decades, the Dutch company's venture into the car industry was disappointingly brief – only 15 years, to be exact. During that time, about 750,000 cars rolled off the production line in Eindhoven, beginning with the DAF 600 that made its debut at the 1958 Amsterdam motor show. Several incarnations followed, including the most popular 33, 55 and 66 models. Some critics joked that DAFs were driven mainly by elderly ladies and were inconsequential, however such blinkered views failed to acknowledge that, in some respects, the cars were ahead of their time, most notably in their automatic transmission. The company's founders, the Van Doorne Brothers, strived to produce a car accessible to all but with some luxuries associated with more expensive vehicles, such as a self-shifting gearbox. Unheard of in small cars, DAF broke new ground by creating the Variomatic transmission – inspired by a belt-driven lathe in the factory – utilising a pulley/belt system to achieve a stepless, automatic gearchange and deliver optimal engine speed for any driving situation. Ironically, the system's popularity increased after DAF stopped producing cars when Ford and Fiat, among others, fitted a continuously variable transmission (CVT) to their smaller models. DAF's short flirtation with the car industry ended in 1973 when Volvo bought the brand. Several factors contributed to the company quitting the car market, including failure to expand sufficiently to compete with rivals and the founders' conservatism restricting the cars' performance potential. This side of the North Sea, DAF only started making headway in the small vehicle market during its final years; before then, import tariffs had been prohibitive until they were lifted when the UK joined the Common Market in 1973. Today, it's estimated that only about 120 DAFs remain on UK roads. We caught up with three devoted owners to understand the enduring appeal of the quirky Dutch cars. I have a long affinity with DAFs because not only did my mother drive one, but I grew up just down the road from the factory in the Netherlands. Often, I'd cycle to school past the plant and see the works rally cars leave for a competition – they drove them to events back then. I bought my 55 in 1997 for £800 after having my eye on it for ages. When it won our concours, I asked the owner for first refusal if he sold it. Luckily, he did. DAFs rarely come up for sale in the UK, but typically I'd expect a 55 Coupé to sell for around £3,500 to £5,500. However, mine is modified and rally-prepared. Similar modified cars have been offered in Holland for about €20,000 (£17,320). For years they were regarded as 'uncool', yet in recent times people have started to seek them out, precisely for that reason. I increased the power of my 55 by, among other things, upgrading the engine to a 1,397cc Renault engine from a Volvo 340. Power has increased from about 50bhp to an estimated 85bhp, although it's getting tired now. I have completed track days, hillclimbs and taken part in classic tours but nothing competitive these days. Now, I just take it out every fortnight – it's certainly a fun car to drive. While the Variomatic transmission makes them unusual to drive, they have a decent chassis, are cheap to run and enjoy fine handling and precise steering. They allow fast progress, particularly in hilly terrain with lots of curves, and always seem to be in the right gear, allowing me to keep up with more powerful cars. Although lightweight, DAFs are strong where it matters, as in the admittedly rather quirky belt-drive CVT transmission; you can tell it was designed by a truck manufacturer. Earlier variants don't have a differential, the difference in rear-wheel speed around bends being taken up by belt slip. That also gives the effect of a limited-slip differential, making them useful rally cars. The only disadvantages with DAFs are that they rust and parts usually have to be sought in the Netherlands, where the Dutch owners' club has several warehouses full of old stock and newly made parts. I paid £2,500 for my DAF in 2016. When I collected it from Yorkshire, the guy asked where my trailer was, explaining that the car hadn't done more than about 25 miles per year so assumed I would trailer it back to Hertfordshire. So, with no AA membership or radio in the car and only a mobile phone for company, I headed off. The DAF performed perfectly, returning 40-plus mpg on the run home – it never missed a beat. I rebuilt the engine recently and now drive the car almost daily. While we also have a Subaru, which is superbly comfortable and quick, its economy around town is frighteningly low, whereas the DAF returns up to 47mpg. In addition, it's exempt from Ulez (ultra-low emission zone) charges in the capital and, being so small, can squeeze into parking bays that would defeat the Subaru. It has a huge boot, too, so a supermarket trip is no problem either. But wherever we go, we frequently receive hoots from the drivers of DAF trucks. They are the easiest car in the world to drive. You start it in gear, which sounds odd but you get used to it, put your foot down and off you go! One pedal to go, one to stop. The engine revs bear no resemblance to the car's speed and the sensation of the car going progressively quicker, but the engine revs remaining constant, takes some getting used to. Unlike 'normal' [torque converter] automatics, DAFs don't creep forwards on tickover, so you simply bring it to a stop using the footbrake. Although it only has a 750cc engine, the way the transmission works means the car is always in the right gear. Being air-cooled, the engine is a little noisy when driven hard, although on reaching a cruising speed the transmission adjusts and the engine becomes quieter. Drum brakes, meanwhile, are fitted all round on the 33 and need a good shove to make an emergency stop; you have to read the road more than in a modern car. People ask why I drive a DAF and it's quite simple: I came from a DAF family. My late father had a penchant for unusual vehicles and, in the late 1960s, bought a 33 van for his electrical business. So impressed was he with the van that he bought a DAF 66 as our family car, while my grandfather opted for a 55. When I passed my driving test, I asked a dealer to look out for a second-hand 33, which he did, so I drove that for several years, before moving to 'sensible' cars. Fast forward to 2016 and partial retirement from work. Wanting something to tinker with, I found this DAF 33 and the circle is complete. I paid £400 for my 1,108cc aubergine-coloured 66 in 2000. It has 18,000 miles on the clock and, to be honest, I don't drive it enough, although it has made two trips to Holland for major DAF events and been back to its birthplace in Eindhoven. DAFs have good road manners plus excellent suspension similar to the Morris Minor: torsion bars in the front, elliptical leaf springs at the rear. When I bought the car, the Variomatic transmission needed work so I demounted it to replace the vacuum diaphragms, which was a heavy but fairly easy job. Also, I replaced parts of the braking system and gained an MOT less than 24 hours before heading to catch the ferry for a week in Holland. In the days when I taxed the car at the Post Office, I was often asked where I stored my truck; few people recall that DAF also made cars. But I love cars which are a technical tour de force and dared to be different, such as the Citroën DS, NSU Ro80, Tatra 613 and the DAF Variomatic. The DAF was the only one I could afford. The interior of my 66 is unmistakably Giovanni Michelotti [among the 20th century's most inventive sports car designers ], like the BMW 1600 and Triumph Dolomite, where form and function conspire to give simple style and an excellent airy cabin with superb visibility. DAFs are well made and apart from the transmission are fairly mainstream. The Renault 1,108cc engine in the 66 is reliable and easy to maintain, while DAF's home-grown 746cc two-cylinder engine – the only car engine ever made by DAF – in the Daffodil, 32 and 33 required no development over its lifetime and is capable of starship mileages.'
